A prospective study on intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration of different durations
Author:
Publisher
Wiley
Subject
Ophthalmology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0420.2007.01113.x/fullpdf
Reference27 articles.
1. Intravitreal bevacizumab for age-related macular degeneration after multiple treatments;Aggio;Graefes Arch Clin Exp Ophthalmol,2007
2. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration;Avery;Ophthalmology,2006
3. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model;Bakri;Am J Ophthalmol,2006a
4. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration;Bashshur;Am J Ophthalmol,2006
5. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration;Boyer;Ophthalmology,2007
Cited by 78 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Anatomical and Functional Outcomes with Prompt versus Delayed Initiation of Anti-VEGF in Exudative Age-Related Macular Degeneration;Journal of Clinical Medicine;2023-12-25
2. Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome;Biomedicine & Pharmacotherapy;2023-04
3. Morphological and functional retinal changes in neovascular age-related macular degeneration treated with intravitreal bevacizumab;Indian Journal of Ophthalmology;2022
4. Real-life results in treating neovascular age-related macular degeneration with anti-VEGF therapy. Analysis of 122 patients from a single centre;Archivos de la Sociedad Española de Oftalmología (English Edition);2021-12
5. Resultados de vida real en el tratamiento de la degeneración macular asociada a la edad neovascular con terapia anti-VEGF. Análisis de 122 pacientes de un solo centro;Archivos de la Sociedad Española de Oftalmología;2021-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3